Evotec and Odyssey Therapeutics Form AI-Driven R&D Partnership

Evotec SE, listed on NASDAQ and Frankfurt Prime Standard, has announced a strategic collaboration with Odyssey Therapeutics. The partnership focuses on using AI-driven R&D to develop new treatments for autoimmune and inflammatory diseases. Odyssey will utilize Evotec's discovery platform and compound libraries to identify drug candidates for high-value disease targets.

This collaboration leverages Odyssey's expertise in disease biology alongside Evotec's advanced technology in drug discovery. The aim is to accelerate research and create differentiated treatments, addressing unmet medical needs in these disease areas. The financial details remain undisclosed, but Evotec is set to receive milestone payments upon successful outcomes.